Eli Lilly and Company announced a significant increase in its full-year 2026 revenue guidance, now expecting to reach between $85 billion and $87 billion, up from its previous forecast of $82 billion to $85 billion. This upward revision follows a strong second quarter in 2026, where the company's adjusted earnings and revenue surpassed Wall Street estimates. The strong performance was largely attributed to the robust demand for its diabetes and weight-loss medications.
Novo Nordisk also raised its financial outlook for 2026, anticipating adjusted sales growth of 0% to -6% at constant exchange rates (CER), an improvement from its prior estimate of -4% to -12%. Similarly, its adjusted operating profit growth is now projected to be 0% to -6% at CER, compared to the earlier -4% to -12%. The company specifically highlighted its GLP-1 product sales, particularly the continued rapid adoption of Wegovy® pill in the US, which has garnered over 5 million prescriptions since its launch, as a key driver for this enhanced outlook. Novo Nordisk reported Q2 2026 adjusted sales increased by 7% at CER and adjusted operating profit increased by 11% at CER.
Lilly's updated guidance also included an increased performance margin expectation, now between 49.0% and 50.5%, up from 47.0% to 48.5%. However, its earnings per share (EPS) guidance was slightly adjusted to $35.50 to $36.50, from the previous $35.50 to $37.00. The company's Q2 2026 worldwide revenue reached $23 billion. This positive financial performance from both pharmaceutical giants underscores the booming market for obesity and diabetes treatments, significantly impacting their earnings and future projections.
The improved outlooks from both Eli Lilly and Novo Nordisk indicate a strong and growing market for their respective weight-loss and diabetes treatments. The companies' ability to exceed analyst expectations and raise guidance suggests a sustained demand that could continue to fuel growth in the pharmaceutical sector, especially in the cardiometabolic disease area.
